Cingulate (CING) Expected to Announce Earnings on Thursday

Cingulate (NASDAQ:CING) is expected to issue its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 18, 2026 at 7:00 AM ET.

Cingulate Stock Performance

CING stock opened at $8.04 on Thursday. The company has a market capitalization of $65.53 million, a price-to-earnings ratio of -2.22 and a beta of -0.77. The business’s 50 day moving average price is $6.45 and its two-hundred day moving average price is $4.79. Cingulate has a fifty-two week low of $3.20 and a fifty-two week high of $11.89.

Insider Activity at Cingulate

In related news, CEO Shane J. Schaffer bought 6,809 shares of the company’s stock in a transaction on Friday, February 6th. The shares were acquired at an average cost of $5.04 per share, with a total value of $34,317.36. Following the completion of the acquisition, the chief executive officer owned 10,175 shares of the company’s stock, valued at $51,282. The trade was a 202.29% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Peter J. Werth bought 19,455 shares of the company’s stock in a transaction on Friday, February 6th. The stock was bought at an average cost of $5.04 per share, for a total transaction of $98,053.20. Following the completion of the acquisition, the director directly owned 117,449 shares of the company’s stock, valued at approximately $591,942.96. This represents a 19.85% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 33,074 shares of company stock worth $166,693 in the last 90 days. 4.33% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Cingulate

Several large investors have recently modified their holdings of CING. Kestra Advisory Services LLC boosted its stake in Cingulate by 29.8% in the 4th quarter. Kestra Advisory Services LLC now owns 122,000 shares of the company’s stock worth $529,000 after purchasing an additional 27,979 shares in the last quarter. Geode Capital Management LLC increased its stake in Cingulate by 43.9% during the 4th quarter. Geode Capital Management LLC now owns 61,035 shares of the company’s stock valued at $265,000 after purchasing an additional 18,629 shares in the last quarter. DRW Securities LLC purchased a new position in Cingulate in the fourth quarter worth about $255,000. XTX Topco Ltd purchased a new position in Cingulate in the fourth quarter worth about $90,000. Finally, Quadrature Capital Ltd bought a new position in shares of Cingulate in the fourth quarter worth approximately $66,000. Hedge funds and other institutional investors own 41.31% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Roth Mkm lowered their price objective on Cingulate from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, November 19th. Ascendiant Capital Markets decreased their price target on shares of Cingulate from $62.00 to $58.00 and set a “buy” rating for the company in a research note on Monday, December 8th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Cingulate in a research report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $37.00.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.